L7759
Lectin from Arachis hypogaea (peanut)
peroxidase conjugate, lyophilized powder
Synonym(s):
PNA, Peanut agglutinin
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.54
UNSPSC Code:
12352202
Form:
lyophilized powder
Biological source:
Arachis hypogaea (peanut)
biological source
Arachis hypogaea (peanut)
Quality Level
conjugate
peroxidase conjugate
form
lyophilized powder
peroxidase activity
≥20 units/mg protein
technique(s)
western blot: suitable
storage temp.
−20°C
Application
General Western Blot Protocol:
- Glycoprotein sample size: 500ng
- Lectin Concentration: 0.1ug/ml
- Load samples at 500 ng of glycoprotein per lane
- Run 4-20% Bis-Tris SDS page gel
- Transfer gel to a PVDF membrane
- Block membrane for 1 hr at RT with RIPA buffer (R0278 Sigma)
- Incubate HRP lectin at 0.1ug/ml with RIPA buffer for 2 hours at RT
- Wash membrane 5 x 5 minutes with 25ml RIPA buffer
- Detect using chemiluminescent substrate (CPS1-120)
Biochem/physiol Actions
PNA does not agglutinate normal human erythrocytes, but strongly agglutinates neuraminidase treated erythrocytes. PNA has potent anti-T activity similar to the anti-T antibody in human sera. The lectin can be used to distinguish between human lymphocyte subsets.
Physical form
Contains sodium citrate
Preparation Note
Prepared from peroxidase (P8375) using a modification of a published method, which favors low molecular weight conjugates. Repurified after conjugation by affinity chromatography.
Other Notes
One unit will form 1 mg purpurogallin in 20 sec from pyrogallol at pH 6.0 at 20 °C.
Still not finding the right product?
Explore all of our products under Lectin from Arachis hypogaea (peanut)
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Product Information Sheet
Matthew R Kudelka et al.
Nature methods, 13(1), 81-86 (2015-12-01)
Protein O-glycosylation has key roles in many biological processes, but the repertoire of O-glycans synthesized by cells is difficult to determine. Here we describe an approach termed Cellular O-Glycome Reporter/Amplification (CORA), a sensitive method used to amplify and profile mucin-type
Timothy J Powell et al.
The Journal of general virology, 100(3), 431-445 (2019-02-05)
A non-replicating form of pseudotyped influenza virus, inactivated by suppression of the haemagglutinin signal sequence (S-FLU), can act as a broadly protective vaccine. S-FLU can infect for a single round only, and induces heterotypic protection predominantly through activation of cross-reactive
Ting-Hsuan Chen et al.
Methods in molecular biology (Clifton, N.J.), 2248, 139-153 (2020-11-14)
Virus-like particle (VLP) technology is an alternative platform for developing vaccines to combat seasonal and pandemic influenza. Influenza VLPs are non-infectious nanoparticles that can elicit effective vaccine immunogenicity in hosts. B-cell-activating factor (BAFF, or BLyS) and a proliferation-inducing ligand (APRIL)